Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Nanotech-based delivery technologies are receiving significant attention.

Overcoming the Poor Solubility of Cannabinoids

Webcasts

Webinar Date/Time: Wed, Jul 19, 2023 1:00 PM EDT

Developing Contamination Control Strategy

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

A partnership between Rentschler Biopharma and Ikarovec will support the accelerated development of novel gene therapies for the treatment of eye diseases.

Rentschler Biopharma, Ikarovec Collaboration Set to Speed Up Ophthalmic Therapy Development 

Feliza Mirasol is the science editor for 

The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.

Nexcella Begins Production of CAR-T Cell Therapy Engineering Batches at US Manufacturing Site

Sandoz’s marketing authorization applications for a proposed biosimilar to denosumab are supported by a comprehensive analytical and clinical data package.

EMA Accepts MAAs from Sandoz for Proposed Denosumab Biosimilar

Webinar Date/Time: Wed, Jun 21, 2023 2:00 PM EDT

Advanced Methodology of Poly(lactic-co-glycolic acid)-based Parenteral Formulations

Webinar Date/Time: Thu, Jun 15, 2023 11:00 AM EDT

Stability of Dry Powder Inhaler Protein Formulations

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.

Discussing Rapid Accurate mRNA Potency Assay Possibilities with Sean Hart

ILC Therapeutics has entered into a strategic partnership with Dechra Pharmaceuticals to develop an atopic dermatitis treatment for dogs.

Scottish Biotech Forms R&D Partnership with Veterinary Medicine Group

With $73 million in financing from investment firms, Myeloid Therapeutics plans to accelerate its lead clinical candidate into Phase I/II development for treating solid tumors.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development